HALB

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Oct 1, 2024

Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System Jackson Center, PA, October 1, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation....

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Sep 11, 2024

Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI Jackson Center, PA., September 11, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd’s LDX technology...

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Sep 9, 2024

Early Pilot Study Data from Veteran Volunteers is Compelling - Part B Jackson Center, PA September 9, 2024 – PRISM MediaWire - Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We hope you have had an opportunity to check out last week’s Press release, Part A. This Part B supplements that release of a few days ago. As always reach out to us if you have any comments or thoughts. Good or bad, we appreciate them! The PTSD market is evolving. It is also...

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Sep 4, 2024

Early Pilot Study Data from Veteran Volunteers is Compelling Jackson Center, PA September 4, 2024 - PRISM MediaWire - Halberd Corporation (OTC: HALB) To our shareholders: As promised, this is the second of three Press Releases on our recent progress. If you have not had a chance to review that last one, on the good news on our Tri-aX™ Nasal Spray for TBI, please do. This one follows the same process. This Press Release is focused on LDN+, as related to Post Traumatic Stress Disorder (PTSD) and...

Halberd Corp. Issues Letter to Shareholders

Aug 26, 2024

JACKSON CENTER, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) today issued the following letter to its shareholders: Halberd Corp. - Taking a Moment to Recenter Our Technical Progress Introducing Tri-ax™ TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal This is the first of a series of three significant Press Releases we plan to issue shortly. Many of our investors have been voicing...

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Jul 24, 2024

Jackson Center, PA July 24, 2024 – Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr. Russell Carr, the project's Principal Investigator, commented: “In the early stages of our Phase II studies, we focused on assessing the efficacy of our innovative Tri-AxTM nasal spray in...

NEWSROOM

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Halberd Corp. Issues Letter to Shareholders

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Contact Us